The 36-month beta value for IPSC is also noteworthy at 1.80. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IPSC is 40.59M, and at present, short sellers hold a 5.93% of that float. The average trading volume of IPSC on June 13, 2025 was 731.92K shares.
IPSC) stock’s latest price update
The stock of Century Therapeutics Inc (NASDAQ: IPSC) has decreased by -3.13 when compared to last closing price of 0.60.Despite this, the company has seen a loss of -5.70% in its stock price over the last five trading days. zacks.com reported 2025-06-06 that Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our ‘Fast-Paced Momentum at a Bargain’ screen.
IPSC’s Market Performance
Century Therapeutics Inc (IPSC) has experienced a -5.70% fall in stock performance for the past week, with a 18.83% rise in the past month, and a -2.53% drop in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are at 4.11% for IPSC. The simple moving average for the past 20 days is 0.69% for IPSC’s stock, with a -41.41% simple moving average for the past 200 days.
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with Rodman & Renshaw repeating the rating for IPSC by listing it as a “Buy.” The predicted price for IPSC in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on August 08, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $5, previously predicting the price at $28. The rating they have provided for IPSC stocks is “Neutral” according to the report published on August 28th, 2023.
Chardan Capital Markets gave a rating of “Buy” to IPSC, setting the target price at $19 in the report published on December 27th of the previous year.
IPSC Trading at 9.16% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.49% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Carr Douglas, who sale 4,904 shares at the price of $0.62 back on Jun 09 ’25. After this action, Carr Douglas now owns 405,982 shares of Century Therapeutics Inc, valued at $3,050 using the latest closing price.
Farid Adrienne, the Chief Operations Officer of Century Therapeutics Inc, sale 552 shares at $0.62 during a trade that took place back on Jun 09 ’25, which means that Farid Adrienne is holding 250,141 shares at $343 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 1.0 for the gross margin
The net margin for Century Therapeutics Inc stands at -0.19. The total capital return value is set at -0.11. Equity return is now at value -10.49, with -6.61 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.4.
Currently, EBITDA for the company is -111.47 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.70.
Conclusion
In summary, Century Therapeutics Inc (IPSC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
